Cabaletta Bio, Inc.

Informe acción NasdaqGS:CABA

Capitalización de mercado: US$595.2m

Cabaletta Bio Dirección

Dirección controles de criterios 4/4

El CEO de Cabaletta Bio es Steven Nichtberger , nombrado en Jan 2017, tiene una permanencia de 9.33 años. compensación anual total es $2.40M, compuesta por 27.5% salario y 72.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.86% de las acciones de la empresa, por valor de $5.09M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 6.3 años, respectivamente.

Información clave

Steven Nichtberger

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO27.46%
Permanencia del CEO9.3yrs
Participación del CEO0.9%
Permanencia media de la dirección4.5yrs
Promedio de permanencia en la Junta Directiva6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Mar 24

Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 27

Cabaletta Bio: Do You Buy With The Insiders?

Summary Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA’s prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development. Strengths include promising pipeline updates, while risks remain around cash runway and clinical progress. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Cabaletta Bio: Finding Optimism In Dire Straits

Summary Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches. With a market cap under $150 million, CABA's stock is a potential bargain if they achieve even partial success in their pipeline. Read the full article on Seeking Alpha
Artículo de análisis • Dec 10

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 22

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Summary I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company’s strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the possibility of oversized returns on investment similar to 2022-23. I rate Cabaletta a Buy for a 12-month outlook, assuming a position size of less than 1% of net portfolio assets, to adequately offset greater-than-normal risk. Read the full article on Seeking Alpha
Artículo de análisis • Sep 04

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 28

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Summary Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries. Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release. Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year. The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for. Read the full article on Seeking Alpha
Artículo de análisis • May 22

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 31

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Summary Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic sclerosis, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Artículo de análisis • Dec 28

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. By way of example, Cabaletta Bio...
Artículo de análisis • Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Artículo de análisis • Jun 04

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example...
Artículo de análisis • Feb 11

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Cabaletta Bio...
Artículo de análisis • Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Jul 07

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steven Nichtberger en comparación con los beneficios de Cabaletta Bio?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$175m

Dec 31 2025US$2mUS$660k

-US$168m

Sep 30 2025n/an/a

-US$159m

Jun 30 2025n/an/a

-US$144m

Mar 31 2025n/an/a

-US$127m

Dec 31 2024US$8mUS$646k

-US$116m

Sep 30 2024n/an/a

-US$104m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$5mUS$597k

-US$68m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$569k

-US$53m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021US$4mUS$542k

-US$46m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$4mUS$516k

-US$33m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$437k

-US$22m

Compensación vs. Mercado: La compensación total ($USD2.40M) de Steven está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.64M).

Compensación vs. Ingresos: La compensación de Steven ha sido consistente con los resultados de la empresa en el último año.

CEO

Steven Nichtberger (64 yo)

9.3yrs
Permanencia
US$2,401,555
Compensación

Dr. Steven A. Nichtberger, M.D., serves as managing partner of GBF Advisors, LLC. Dr. Nichtberger is an adjunct professor at The Wharton School at the University of Pennsylvania. He is Co-Founder of Cabale...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 5.1m
David Chang
Chief Medical Officer6.9yrsUS$1.24m0.0054%
$ 32.1k
Gwendolyn Binder
President of Science & Technologyno dataUS$1.26m0.019%
$ 114.3k
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Anup Marda
Chief Financial Officer7.3yrsUS$1.53msin datos
Qing Yuan
Chief Technology Officer1.9yrssin datossin datos
Samik Basu
Chief Scientific Officer4.5yrssin datossin datos
Michael Gerard
General Counsel & Secretary4.7yrssin datossin datos
Heather Harte-Hall
Chief Compliance Officer4.5yrssin datossin datos
Nicolette Sherman
Chief Human Resources Officer1.5yrssin datossin datos
Arun Das
Chief Business Officer4.3yrssin datossin datos
4.5yrs
Permanencia media
52yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de CABA se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Steven Nichtberger
Co-Founder9.3yrsUS$2.40m0.86%
$ 5.1m
Michael Milone
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Aimee Payne
Co-Founder & Co-Chair of Scientific Advisory Boardno datasin datossin datos
Richard Henriques
Independent Director7.3yrsUS$152.17k0%
$ 0
Carl June
Member of Scientific Advisory Board5.8yrssin datossin datos
Mark Simon
Independent Director7.6yrsUS$140.91k0.095%
$ 562.9k
Scott Brun
Independent Director4.9yrsUS$136.84k0%
$ 0
Iain McInnes
Member of Scientific Advisory Board6.3yrssin datossin datos
Jay Siegel
Member of Scientific Advisory Boardno datasin datossin datos
Georg Schett
Member of Scientific Advisory Board4.3yrssin datossin datos
Shawn Tomasello
Independent Director2.8yrsUS$119.17k0.014%
$ 83.0k
Catherine Bollard
Independent Director7.1yrsUS$145.57k0.0033%
$ 19.7k
6.3yrs
Permanencia media
64yo
Promedio de edad

Junta con experiencia: La junta directiva de CABA se considera experimentada (6.3 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/24 01:41
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Cabaletta Bio, Inc. está cubierta por 15 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI